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Summary
Cryptocotcus neoformans is a ubiquitous fungus that can cause serious infections in humans. The
fungus has a polysaccharide (C. neoformans capsular polysaccharide; CNPS) capsule that contributes
to its pathogenicity and can elicit an antibody response. Nevertheless, only 4 of 60 BALB/c mice
chronically infected with C. neoformans had a detectable increase in serum anti-CNPS. The sera
of three responder mice contained both IgM and IgG anti-CNPS antibody, and the titers of
A and K anti-CNPS antibody were approximately equal. Eight IgM and one IgG3 monoclonal
antibodies (mAbs) were generated from the spleen of one responder mouse, and one IgA was
generated from the spleen of another mouse. Seven of the IgMs, the IgG3, and the IgA mAb
had X light chains and were specific for serotype D CNPS. Molecular analysis confirmed that
this was a highly restricted antibody response. All of the D-specific antibodies used V441, JH3,
and either Va2/Jt,2 or Vß,1/Jal, and all had the same heavy chain CDR3 amino acid sequence,
even though there were differences in the nucleotide sequence of the N/D segment. One IgM
mAb reacted with both serotype A and D CNPS, and this mAb used different V andJH genetic
elements and had tc light chains. All the anti-CNPS mAbs used J proximal V gene elements
that have previously been shown to bind dextran and other polysaccharides. Sequence and Southern
blot analysis indicate that the serotype-D CNPS-specific mAbs arose from only a few precursor
B cells.
T
he fungus Cryptococcus neoformans can cause serious in-
fection in humans, and immunocompromised individ-
uals are at particular risk (1). C. neoformans causes disease in
up to 10% of individuals with AIDS (2). In the setting of
AIDS, cryptococcal infections are usually incurable and often
fatal (3). C. neoformans has a large polysaccharide capsule that
inhibits phagocytosis by macrophages (4). The capsular poly-
saccharide is poorly immunogenic and causes the phenomenon
of immune paralysis in mice (5-7). Structural differences in
the capsular polysaccharides allow the grouping ofcryptococcal
strains into five serotypes, A, B, C, D, and AD (8, 9). Sero-
types A and D cause the majority of infections in AIDS pa-
tients (10).
Cellular immunity is believed to provide the primary host
defense against cryptococcosis (1) . The role of humoral
immunity to the C. neoformans capsular polysaccharide
(CNPS)' in protection is uncertain. Favoring an important
role for antibodies are the observations that: (a) individuals
with cryptococcal infection have a better prognosis if they
1 Abbreviation used in this paper: CNPS, Cryptococcus neoformans capsular
polysaccharide.
have serum antibodies (11); (b) antibody enhances phagocy-
tosis by macrophages (12), mediates fungistasis by NK cells
(13), and facilitates leukocyte killing (14, 15); and (c) passive
administration of an IgG1 murine mAb produced a sixfold
increase in the survival of lethally infected complement-
deficient mice (16), and potentiated the therapeutic action
of Amphotericin B (17). However, certain observations are
not consistent with an important role for humoral immu-
nity. For example, B cell-deficient mice are not especiallysus-
ceptible to cryptococcal infection (18); vaccination with
immunogenic polysaccharide glyconjugates has not been pro-
tective in mice (19); and passively administered mAbs failed
to protect mice in another model (20). Thus, many in vitro
observations indicate an important role for antibody by en-
hancing cellular immunity, whereas some in vivo experiments
have confirmed a protective effect and some have not. The
finding that AIDS patients lack anti-CNPS IgG (21) raises
the possibility that lack ofantibody contributes to their marked
susceptibility to cryptococcus.
The overall aim ofour work has been to find mouse mAbs
to CNPS that are protective against cryptococcus. This paper
reports the serologic characterization of the serum response
to cryptococcal infection and the generation ofmAbs to CNPS
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are continuing and the results will be described elsewhere.
We have determined theprimarystructureof the anti-CPNS
mAbs from their mRNA sequences and studied the Ig gene
rearrangements in the hybridomas to gain a more detailed
understanding of the genetic and molecular basis for there-
sponses.
Materials and Methods
C. neoformans.
￿
Thestrain used to infect mice wasisolated from
an AIDS patient with cryptococcal meningitis at Bronx Hospital
MedicalCenter, andis referred to as "GH". Standard serotype strains
A, B, C, and D (nos. 24064, 24065, 24066, and 24067, respec-
tively) were obtained from the American Type Culture Collection
(ATCC) (Rockville, MD).Thestrains were maintainedin Saboraud's
agar slants at 4°C. CNPS wasprepared as describedby others (22,
23). The concentration of polysaccharide was determined by the
phenol-sulfuric acid method (24).
ELISA. ELISA plates (no. 25801; Corning Glass Works,
Corning, NY) were coated with CNPS by incubating 50 ial of a
10 ug/ml solution of CNPS in 0.02 M PBS, pH 7.2, in each well
at room temperature overnight. The concentration of protein in
GH CNPS wasdetermined with aprotein assay(Bio-Rad Labora-
tories). Plates were blocked with a solution of 1% BSA in PBS.
Alkaline phosphatase-conjugated goat anti-mouse IgM, IgG1,
IgG3, IgG2a, IgG2b, IgA, rc, and Xreagents (Fisher Biotech) were
used to develop the ELISA.
Mice.
￿
BALB/c mice were obtained from the National Cancer
Institute(Bethesda, MD). Themice were infected with cryptococci
intraperitoneally. Before inoculation, the yeast was washed with
PBS and counted in a hemocytometer. Mice were bled from the
retro-orbital sinus, and sera were separated by centrifugation and
stored at -20°C.
Monoclonal Antibodies.
￿
mAbs to GH CNPS were made from
chronically infected BALB/c mice with high serum titers. The use
of spleens from infected mice posed the potential problem of hy-
bridoma cell culture contaminationwith cryptococci. We avoided
this problem by treating the mice with Amphotericin B and the
hybridoma cultures with Nystatin. The mice were treated with
Amphotericin Bintraperitoneally (5-15 mg/kg totaldose) during
the week before harvesting the spleen to decrease the number of
cryptococci in their tissues. We cultured the brain, heart, lungs,
liver, and kidney from amouse that hadreceived 15 mg/kgofAm-
photericin B, and foundcryptococci only in brain tissue. Hybrid-
omas were made by fusing splenocytes with NSO myeloma cells
at a 4:1 ratiowith polyethylene glycol by aprotocol describedpre-
viously (25). Nystatin (Gibco Laboratories,GrandIsland, NY) was
added to the hybridoma cultures at a concentration of 100 U/ml
1 d after the fusion. Hybridomas were screened by ELISA using
plates coated with 50 141of 10 pg/ml GH CNPS. Cells from posi-
tive wells were cloned in soft agar.
The mAb isotype and light chain type were determined using
goat anti-mouse isotype andlightchain-specific alkaline phospha-
tase-labeled antibodies. Hybridoma supernatants containing the
mAbs were used forbinding studies. ThemAb concentration was
determined by ELISArelative to standards of thesame isotype and
ofknownconcentrationforall antibodies except 4113. Because the
goat anti-IgG3 reagents were of low affinity, the 4113 mAb was
purified using an anti-mouse IgGcolumn, dialyzed against PBS,
and its concentration was determined by a protein assay (Bio-Rad
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Laboratories) using a myeloma IgG3 as a standard rather than by
ELISA.
mRNA Sequencing.
￿
Total cellular RNA was prepared by the
guanidinium method, and poly(A)' mRNA was isolated using an
oligo-dT affinity column. Thenucleotide sequence of theantibody
mRNAs was determined using a modification of the method of
Geleibter et al. (26). The following oligonucleotides were used as
primers: TGGATGGTGGGAAGATG (rc), TCTCGCAGGAGAC-
GAGGGGGA (Ft), CCTGAGAATCTGACAGGAACA (VX), TGT
TCTTGGCATTGTCTCTG (V.Ga150.1), TACAGCGTATTTTT
GGCGTT (V441), CGTGAGGGCAGCCTTGTCTCC (5' VX),
GAGTGTCAGTGGGTAGATGGT (Cot), GAGAGCAGAAATA-
AACTCCC (VK5.1), TGCACAGGAGAGTTTCAG (5' V441),
GGTGAGGGCAGCCTTGTCTCC (5' VX), GACCCCAGAA-
AATCGGTT (5' VK5.1), ACCTAGGACAGTGACCTT aa2),
CACCAGATTCTTATCAGA (P), AAGTAGGCCTTTGACAAG-
GCA (.y3). The oligonucleotide primers were made in the DNA
synthesis facility in our institution. For 4113, in addition to se-
quencing directly from the mRNA, V cDNA was made using
the primer AAGTAGCCTTTGACAAGGCA and then amplified
by the PCRusingthat same primer andGAGGTGAAGCTTCTC-
GAGTCT The total PCR product was then sequenced using the
Sequenacekit (United States Biochemical Corp., Cleveland, OH)
to confirm the 4H3 CDR3 sequence.
Southern Blot Hybridization.
￿
DNAwas extractedfrom theNSO
myeloma, the hybridomas, andBALB/c liver. Restriction enzyme
fragmentswere separatedin 0.8-1.0% agarosegels andtransferred
to modified Nylon membranes(GeneScreen) by blotting using 10x
SSC (1x SSC is a 0.15 M NaCl and 0.015 M sodium citrate solu-
tion). Blots were prehybridized in a solution of denatured salmon
sperm DNA (0.5-1.0 mg/ml) in 5x SSC, 7% SDS, 10x Den-
hardt'sreagent, 10% dextran sulfate, in 20 mM sodium phosphate
buffer (pH 7.2) at 65°C. Hybridization was performed underthe
same conditions with DNA probes labeled with .y-['2p]-dCTP
usingrandom primers (Boehringer Mannheim Biochemicals). After
hybridization, blots were washed initially with a solution of 3x
SSC, 5% SDS, 10x Denhard's Reagent, in 20 mM phosphatebuffer,
pH 7.2, and finally in a solution of 1x SSC and 1% SDS. Blots
were washed at 65°C.
Immunofluorescence
￿
A suspension of yeast (106 to 10' yeast/ml)
in PBS was air dried on glass slides. The slides were first blocked
with 1% BSA in PBS, then incubated with cell supernatants con-
taining mAb at a concentrationof 1 Pg/ml, washed, and then in-
cubated with fluorescein-labeled anti-mouse IgM.
Results
Mouse Antibody Response to Infection.
￿
The sera ofBALB/c
mice infected intraperitoneally with sublethal innocula of 104
to 106 cryptococci (GH) were assayed for the presence of an-
tibody to GH CNPS. The antibody titer was measured by
ELISA after serial dilution on plates coated with GH CNPS.
Uninfected animals usuallyhad serumtiters of 1:50to 1:100,
whichprobably reflect the presence ofcrossreactive antibodies.
Of 60 infected mice, only four had titers of anti-CNPS anti-
body >1:200. Fig. 1 shows the serum titers of IgM, IgG,
rc, and X at several times after infection for three of themice
that had high titers of anti-CNPS. The fourth animal was
killed earlyto fuse its spleen. Thesedata show that: (a) anti-
body titers peak between days 11 and 18 and then slowly de-
cline with time even though these animals are chronicallyinfected ; (b) both IgM and IgG are present ; (c) in many of
thebleedings, the titer of X is roughly equivalent to that of tt .
Monoclonal Antibodies. Spleens from four infected mice
were used in this study. Two of the spleens came from the
mice with the highest titers of antibody to CNPS . Since it
was possible that the low serum titers measured for the
majority of mice were the result of antibody sequestration
in complexes with polysaccharide, we also fused splenocytes
from two mice with low titers ofantibody to CNPS (<1:200) .
Each spleen was handled separately. Hybridomas producing
mAb to CNPS were obtained only from the spleens of the
animals with high serum titers of anti-CNPS antibody. One
of the two productive fusions used a spleen harvested on day
33 ofinfection (mouse 3 in Fig. 1), and it yielded sevenIgM-
and one IgG3 mAb-producing hybridomas. The other produc-
tive fusion used a spleen harvested on day 17 of infection,
and it yielded only one IgA hybridoma-producing mAb.
Serological Characterization ofthe Monoclonal Antibodies.
￿
The
mAbs were initially characterized for heavy chain isotype,
light chain type, and binding to CNPS from standardATCC
A, B, C, and D serotypes and the GH strain (Table 1) . Al-
though the serotype of the GH strain used in this study was
not initially known, the reactivity of our panel ofmAbs with
GH CNPS indicates that GH belongs to either theD or A/D
serotypes (9) . With the exception of 21132, all themAbs had
X light chains and reacted only with serotypeD CNPS. The
21132 mAb had a K light chain and it reacted with CNPS
from both serotypes A andD. This indicates that 21132 recog-
nizes a different epitope than the other mAbs .
Binding of 14A12 (,,A) or 21132 (ILK) mAbs to cryptococci,
followed by staining with fluorescein-conjugated anti-mouse
IgM, produced capsular fluorescence like those reported pre-
viously for both immune polyclonal sera (19) and for other
anti-CNPS mAbs (23) (data not shown) . This confirms that
these mAbs bind to the cryptococcal capsule .
Fig. 2 shows binding curves of 14A12 (AX) and 21132 (AK)
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Figure 1 .
￿
Serum antibody responses ofthree responder
BALB/c mice infected with the GH cryptococcal strain .
The bars represent the antibody titer in terms of IgM,
total IgG, ic, and X at various time points after infection .
Antibody titer was measuredby serial dilutions on ELISA
plates coated with 10 Ftg/ml ofGH CNPS . The titer was
defined as the serum dilution that gave an optical density
at 405 nm, which was at least 1 .5 times the background
in the ELISA . The three mice (aged 9-12 mo) were in-
fected with sublethal innocula of 104 to 106 cryptococci
intraperitoneally. The IgG fraction of mouse 3 consisted
exclusively of IgGl and IgG3 subtypes.
to GH CNPS. The binding curves of the other IgMA anti-
bodies, 7B13, 11E2, 12G5, 20B5, and 20C5, are indistinguish-
able from those of 14A12 and are not shown here . Since we
found no significant differences in the binding of theseIgMA
mAbs toGH CNPS or in theirmRNA nucleotide sequences
(see below), 14A12 was designated as the prototype for the
IgMA group . The binding curves of 14A12 and 21132 are
Table 1 .
￿
Characteristics ofCNPS Binding Antibodies
Class, light chain usage, reactivity with CNPS of serotypes A, B, C,
D, and GH, and the V  and VL usage for the anti-CNPS mAbs . The
symbols + and - denote binding and lack of binding, respectively, to
ELISA plates coated with 10 ug/ml of CNPS from the different sero-
types . The 15C6 mAb is separated from the others by a space because
it was generated from the spleen of a different mouse . The V  , J., VL,
and JL were determined from the Ig mRNA sequences . The V50 .1 and
V441 are gene elements belonging to the 7183 and X-24 gene fami-
lies, respectively (29) . V K5 .1 has been reported in antiprenolol mAbs
(32) . The N/D segment sequences are shown in Fig . 4 .
mAb Class A B
Serotype
polysaccharide
C D GH V  Jx V L JL
21132 IgMrc + - - + + 50.1 2 VK5.1 JK1
14A12 IgMA - - - + + V441 3 V),2 Ja2
11E2 IgMA - - - + + V441 3 Vat Jx,2
7B13 IgMA - - - + + V441 3 Vat Ja2
12G5 IgMA - - - + + V441 3 Va2 Jx,2
20C5 IgMA - - - + + V441 3 Vx,2 Jx2
20B5 IgMA - - - + + V441 3 V),2 Ja2
4H3 IgG3A - - - + + V441 3 Val JX1
15C6 IgAA - - - + + V441 3 V),2 Jr2E
c 0.6
G
O
0.8k,
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Figure 2.
￿
ELISA binding data of the 14A12 and 21132 mAbs to GH
CNPS. The graph shows a plot of OD4o5 vs. GH CNPS concentration,
where the mAb concentration is kept constant at 1 ug/ml and the CNPS
concentration is varied. The binding curves ofthe otherIgMX antibodies,
71313, 11E2, 12G5, 20115, and 20C5, were like that of the 14A12 mAb
and are not shown here. Note that the hybridoma supernatants were screened
using plates coated with 10 ug/ml of GH CNPS.
different for CNPS concentrations of <10 /.kg/ml (Fig. 2).
Since the 14A12 (AX) and 21D2 (Arc) mAbs bind to different
epitopes (Table 1), the differences in binding shown in Fig.
2 could reflect variation in epitope density, a higher intrinsic
affinity for the 21D2 mAb, or both.
In addition to the seven IgM mAbs described, we also ob-
tained an IgG3A (4113) and an IgAA (15C6) mAb. These
two mAbs have the same serotype specificity as those of the
14A12 class, binding only to serotype D and GH CNPS (Table
1). Soluble CNPS inhibited mAb binding to CNPS-coated
ELISA plates, as shown in Fig. 3 for 21132 (Arc), 14A12 (AX),
4113 (-Y3X), and 15C6 (orX). The binding curves are not
directly comparable since the two IgMs, 21132 and 14A12,
bind to different epitopes, and since the 14A12, 4113, and
15C6 mAbs are ofdifferent isotypes that differ in avidity (Table
1). Of the two IgMs, 21132 requires 102 less CNPS to in-
hibit its binding than 14A12, and hence, it has higher ap-
parent affinity. The 4113 (y3X) mAb is inhibited by the
lowest concentration of soluble CNPS, and hence, this mAb
has the highest apparent affinity ofthe four antibodies. Using
the method of Nieto et al. (27), we have calculated apparent
binding constants (aK,s) in the range of 106 to 108 M- t for
these four mAbs (see Fig. 3 legend) . The three isotypes iso-
lated in this study, namely IgM, IgG3, and IgA, all can bind
antigen more strongly than expected from the intrinsic binding
constants of their individual binding sites, as a result of ei-
ther higher avidity due to polymer formation (IgM and IgA)
or because of cooperative binding through Fc interactions
(IgG3) (28) .
If Region Use and Antibody Sequences.
￿
The mAb mRNAs
were sequenced to determine antibody structure and variable
gene usage. Based on the nucleotide sequence data,our mAb
set can be classified into two groups that correlate with their
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Crypfococcol Copsulor Polysaccharide (GH) (pg/ml)
Figure 3.
￿
Inhibition of mAb binding to CNPS-coated ELISA plates by
soluble CNPS. The plates were coated with a solution of 10 ug/ml of
GH CNPS. The antibody and CNPS were incubated for 1.5 h at 37°C.
We calculated apparent binding constants (ak,) of 8 x 108 M-1, 2 x
108 M -1, 7 x 107 M -1, and 8 x 106 M-1 for the 4113, 21132, 15C6,
and 14A12 mAbs, respectively, using the method described by Nieto et
al. (27). For the ak, calculation, we assumed a molecular mass of 800,000
daltons for the polysaccharide (41). For 4H3, an IgG3 mAb, we observed
considerable variability in the shape of the curves, and suspect that this
variability reflects cooperative binding effects that can occur with this sub-
class (26). The significance of the different slopes is not understood.
serotype specificity (Table 1). One group consists of the 14A12
class (AX), 4H3 (y3X), and 15C6 (oA), which bind only
serotype D CNPS. The second group consists of 21132 (Arc),
which binds both A and D CNPS.
All of the serotype D-specific X mAbs have a heavy chain
variable region (V.), encoded by VH441 (VGal39.1) (29), a
small "diversity" segment consisting of four codos, and JH3
(Table 1; Fig. 4). The light chain variable region (VL) is en-
coded by VX2/JX2 for the 14A12 class and 15C6 and by
VX1/JX1 for 4113. The fact that all of these mAbs have a
variable region structure that is identical or nearly identical
indicates that all recognize the same epitope. No somatic mu-
tations were found in the sequences of the V441, JN3, VA2,
and JX2 genetic elements used in the mAbs of the 14A12
class (AX) (data not shown). The members of the 14A12 class
also have the same sequences in their diversity segments (Fig.
4). We could not identify the D segments in 14A12, 4113,
or 15C6 among reported germline D sequences even if we
looked for unusual reading frames, inversions, or deletions.
Since these sequences contain many G residues, they may be
largely or completely N-sequence, and hence, we referto this
segment in our mAbs as N/D.
Five differences distinguish 4113 (y3A) from the 14A12
(AX) group: (a) the presence of a silent mutation in codon
64 (CTA to CTT) of the V441 (data not shown); (b) a
replacement mutation in codon 104 (GCT to TCT) resulting
in a valine to serine change in JH3 (Fig. 4); (c) the codon
GGT instead of GGG at position 97 (in the N/D sequence),
which represents either a somatic mutation ofthe 14A12 N/D
sequence or a different N/D segment reflecting a differentVH441 N/0
￿
JH3
arg
VH14A12 AGA CGT
VH7813
VH13E2
VH12G5
VH2085
VH20C5
VH4H3
VH15C6
1 1
A GGG GGG TC
￿
TTT GCT TAC TGG GGC CAA GGG ACT CTG GTC ACT GTC TCT GCA
--- --- ---
￿
--- --- --- --- --- --- --- --- --- --- --- --- --- ---
clonal origin of theB cell encoding4H3 (Fig . 4) ; (d) an addi-
tional codon at the 3' end of the JH3, which is not encoded
by either JH3 or Cy3 (30) (Fig. 4) . The origin of this extra
codon is not known . One possibility is that somatic muta-
tion occurred in the intervening sequence (31) resulting in
altered RNA splicing. The first three nucleotides in the in-
tervening sequence downstream of JH3 are GGT (30), and
a single somatic mutation could have changed this codon to
GCT; and (e) the 4H3 VL uses Vat/J),1 instead of Vx2/Ja2
Figure 5 .
￿
Autoradiograph of Southernblot containing EcoRl digests
ofDNA from BALB/c liver, NSO myeloma, and the anti-CNPS hybrid-
omas probed with the BamH1-Eco R1 J.3 -J. (J11) probe. (B) A map of
the rearranged restriction fragments .
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Figure4 .
￿
VDJjoining regionfor the 14A12 group, 4H3,
and 15C6 mAbs . Comparison of the 14A12 and 15C6
CDR3 sequence reveals four base differences in this re-
gion that result in the same amino acid sequence because
ofthe degeneracy of the code . Dashed lines indicate iden-
tity. Replacement mutations are in capital letters, whereas
silent mutations are in lower case letters . 4H3 has areplace-
ment mutation in the second codon of the J, leading to
the replacement ofvaline for serine . The 4H3 mAb also
has an extra codon GCT at the junction between J3
and Cy3 .
(Table 1) . The Vr1 of4H3 has two somatic mutations, one
resulting in replacement of alanine by valine at position 57
(GCT to GTT), and one silent mutation in the J,,1 at posi-
tion 107 (CTC to CTG) (data not shown) .
The 15C6 (oA) mRNA was generated from a different
mouse than the other anti-CNPS mAbs . The construction
of 15C6 used the same gene elements as used in the 14A12
group, namely VH441, JH3, Vx2, and J,,2 . Remarkably, 15C6
has the same CDR3 protein sequence as the mAbs in the
14A12 class and 4H3, even though itsmRNA sequence has
three base differences in the N/D segment (Fig. 4) . No so-
matic mutations were found in the 15C6 V441, Vx2, J) ,2
genetic elements, but one silent mutation occurred in the
first codon of JH3 (Fig. 4) .
As expected from its different serotype specificity, the con-
struction of the 21D2 A-D-reactive V and VL used different
genetic elements than those found in the serotype D-specific
mAbs (Table 1) . The VH of21D2 is composed ofV50 .1 (29)
(a member of the 7183 gene family), an unidentified D, and
Figure 6 .
￿
Autoradiograph of Southern blot containing HindIII digest
ofDNA from BALB/c liver, NSO myeloma, and the anti-CNPS hybrid-
omas probed with the 2.7-kb HindIIl fragment JK1-5 probe .JH2. The D segment of 21D2 has seven codons (CGGGAC-
AGCTCGGGCCAGTAC), and thus is larger than that found
in the serotype D-specific mAbs. The light chain of 21D2
is composed of the VK5.1 (32) and Jx2 gene elements (data
not shown). Although no somatic mutations were identified
in the genetic elements used in the 21D2 mAb, the last codon
of the Vx5.1 sequence (at the VJ junction) was CCA instead
of CCT (32), resulting in a silent substitution.
In summary, the sequence data revealed: (a) a marked re-
striction in variable region gene usage in the serotype
D-specific set of mAbs; (b) a few somatic mutations in the
IgG3 and IgA mAbs; (c) the use of VN gene elements from
3' proximal gene families that have previously been reported
in antipolysaccharide antibodies (29); and (d) N/D segments
with different base sequences but identical amino acid se-
quences in the serotype D-specific mAbs.
Southern Blot Analysis ofthe Ig Gene Rearrangements.
￿
The
sequence data suggested that the antibodies from the first
fusion were the products of at least three different B cell clones
that served as precursors to the 21D2 (p.rc), the 4H3 (-Y3X),
and the 14A12 group (,uX) hybridomas. To further examine
the clonal relationship of the members of the 14A12 class
and 4H3, we studied the restriction patterns oftheir produc-
tive and nonproductive alleles. Fig. 5 shows an autoradio-
graph of a Southern blot with EcoR1 fragments of DNA
from BALB/c liver, the NSO fusion partner, and the various
anti-CNPS hybridomas after hybridization with the Jti
probe for the Jx3JH4 segment. A single band of 6.6 kb is
present in liver DNA corresponding to the germline size of
the EcoR1 fragment containing JH3J4. A single band is
also present in the NSO DNA, but it migrates slightly slower
(6.8 kb) than the liverband. The restriction patterns obtained
with Jll for the serotype D-specific anti-CNPS hybridomas
(71313, 11E2, 12G5, 14A12, 20135, 20C5, 4113, and 15C6)
all show the 6.8-kb fragment from the NSO fusion partner,
and a new rearranged band at 2.1 kb. Some of the hybrid-
omas also have a weak band of 6.6 kb directly below the 6.8-
kb band, which presumably corresponds to either an unrear-
ranged allele or to another rearrangement. The size of the
2.1-kb fragment is consistent with that expected from rear-
rangement of the V,,441 gene to JH3 (29) (Fig. 3 B). These
Southern blot data strongly suggest that the 14A12 group
(ttX) and the 4143 (-Y3A) hybridomas have identical V.-J.
rearrangements. The DNA from 15C6 (which originatesfrom
the spleen of a different mouse) shows three bands; the 6.8-
kb band from the fusion partner, and bands at 2.1 and 1.9
kb, which presumably correspondto the productive and non-
productive rearrangements, respectively. The 21D2 hybridoma
has the NSO band at 6.8 kb, a band at 6.6 kb, and a new
band at 3.3 kb, which presumably corresponds to its produc-
tive rearrangement (Fig. 5). The size of the 21D2 band at
3.3 kb is consistent with rearrangement of the V50.1 to
JH2 (29).
Since J,, rearrangements usually precede A rearrangements
(33), we also analyzed the JK locus rearrangements of the
14A12 (AX) group and 4113 ('y3A). Fig. 6 shows an autora-
diograph ofa Southern blot ofHindIII DNA restriction frag-
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ments probed with the JR1-5 probe. All hybridomas have a
band at 6.6 kb that comigrates with the single band in NSO
DNA, and presumably comes from the fusion partner. In
addition, the blot reveals three types of J,, locus rearrange-
ments in the 14A12 group: (a) 71313 and 20135 have two bands
each at 12 and 2.5 kb; (b) 11E2, 12G5, and 14A12 have two
bands each at 2.7 kb (suggesting that at least one allele is
in the germline configuration) and at 9.4 kb; and (c) 20C5
has only the band at 6.6 kb corresponding to that of NSO,
indicating that the J,, locus was lost either in the precursor
B cell or after hybridoma formation, making it impossible
to assign to either group. The 4113 (-y3X) hybridoma has
different J locus rearrangements than those found in the
14A12 group, having one band at 5.2 kb and another band
>23 kb. Also shown in Fig. 6 is the 21D2 (AK) hybridoma,
which has two bands at 4.0 and 9.4 kb in addition to the
NSO fusion partner band.
Discussion
The decision to generate anti-CNPS mAbs from crypto-
coccus-infected mice was made with the premise that such
antibodies would be elicited by biologically relevant epitopes.
Eight mAbs (seven IgM, one IgG3) were generated from the
fusion of one spleen, and one IgA mAb was generated from
another spleen. The serum antibody titers and the isotype
distribution of the mAbs generated suggests that the hybrid-
omas obtained generally reflect the animals totalB cell response.
Since IgM has an intravascular half life (tth) of 8.5 h, whereas
both IgG1 and IgG3 have tth of -200 h (34), the ratio of
IgM to IgG hybridomas obtained in the first fusion is consis-
tent with the IgM and IgG anti-CNPS serum titers of 1:400
and 1:800, respectively, measured on the day before the fu-
sion. Most of the mAbs had X light chains, consistent with
the A-rich serum antibody response. However, despite the
fact that the serum titers of K and A anti-CNPS antibodies
were roughly equal, only one is mAb (21D2) was isolated
from two protective fusions. The paucity of is anti-CNPS
hybridomas might be explained by either a preferential as-
sociation of Klight chains with IgG (which have much longer
serum tth) or the absence of K anti-CNPS B cells in the
spleen lymphoid compartment.
The following lines of evidence indicate that our mAbs
recognize polysaccharide epitopes. (a) The mAbs are sero-
type specific and serotype specificity has been assigned to poly-
saccharide structural determinants (9, 35-37); (b) immu-
nofluorescence shows that 14A12 and 21D2 bind to the
polysaccharide capsule; (c) the polysaccharide preparations used
in the ELISAs had an extremely low level of protein relative
to polysaccharide concentration (<2 ng/ml, or <1:5000 ratio
ofprotein/polysaccharide by weight), and this amount of pro-
tein is below the usual detection threshold in the ELISA (38);
and (d) all the mAbs use gene elements that have been as-
sociated with antipolysaccharide antibodies such as V441
and VGa150.1 (28, 39, 40).
mAbs to CNPS have been generated by three other groups
using animals immunized with either CNPS (22), CNPS con-jugated to sheep erythrocytes (41), or CNPS conjugated to
BSA (35). Our mAbs came from B cells stimulated during
cryptococcal infection. They are different from previously de-
scribed mAbs in that most are serotype D-specific antibodies
that use X lightchains. Using polyclonal antisera and sequential
absorbtions, Ikeda et al. (9) developed a numerical taxonomy
system for categorizing CNPS serotype according to eight
antigenic factors, and concluded that serotype was determined
by only a few antigenic determinants. In the Ikeda scheme,
antigenic factor 8 is a D-specific antigen, and factor 3 is found
shared by the A and D serotypes. Since the 14A12 group,
4143, and 15C6 bind only serotype D, they probably recog-
nize antigenic factor 8. Since the 21D2 mAb binds to both
serotypes A and D, it probably recognizes antigenic factor
3. The specificities ofour mAbs are thus consistent with and
support the Ikeda (9) classification.
The molecular characterization of the mAbs revealed a
striking degree of restriction in variable gene element usage
in the serotype D-specific mAbs. In fact, the large propor-
tion of X antibodies in the serum antibody response to GH
CNPS suggests a restricted response since X antibodies are
relatively rare in the mouse and comprise only 3-5% of the
total antibody pool. There are only two Va genes and they
share a high degree of homology (33). All of our X anti-
bodies were specific for serotype D CNPS. Restriction in vari-
able gene element usage has been reported in responses to
some carbohydrates such as 3-fucosyllamine (40). However,
other carbohydrates such as group A streptococcal polysac-
charide (42) and dextran (43) elicit antibodies using a variety
of variable gene elements.
The V of all of the serotype D-specific antibodies used
V441, an N/D segment consisting of four codons, and JH3.
The V441 is a member of the X-24 V family, which is the
smallest V family and consists of only two gene elements
(44) . V441 has a potential glycosylation site in the CDR2
domain. V glycosylation has recently been shown to in-
crease the affinity of an antidextran antibody (45) and may
be important in the binding to CNPS. V441 usage has been
reported in several anticarbohydrate mAbs that recognize very
different carbohydrate structures (29, 40, 45). Since most of
these mAbs use V441 in its germline sequence, it has been
proposed that the fine specificity of these mAbs for carbohy-
drate epitopes resides in their CDR3 and/or light chains (39,
40). The fact that the N/D segments ofall serotype D-specific
mAbs, including antibodies from two different animals, en-
code the same protein sequence suggests that the structure
of CDR3 is important for binding. In addition, serotype D
epitope specificity may require the use of X light chains.
Since VDJ recombination and the introduction of N se-
quence usually occur before light chain rearrangements (46),
the most conservative interpretation of the sequence and
Southern blot data is that there was a single pre-B cell precursor
for all members ofthe 14A12 group (PA) and for 4143, which
assembled its heavy chain gene and underwent subsequent
cell divisions. Two such subclones then carried out different
nonproductive K rearrangements and went on to use the same
Vx and Jx elements to form identical productive light chains
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resulting in the 14A12 group. Since 4143 has different Jx rear-
rangements and uses different Va/J,, gene elements than the
14A12 group, its ancestor may have been a third subclone
of the original B cell precursor. In this interpretation, the
one base difference in the N/D segment of 4143 compared
with those of the 14A12 group is attributed to somatic mu-
tation. It is noteworthy that the response that generated the
14A12 group (and possibly 4143) appears to be a second ex-
ample where a single pre-B cell gave rise to antigen-specific
B cells with different light chain gene rearrangements (47).
However, if one base difference in the 4143 N/D sequence
arose during VDJ formation rather than as a result of so-
matic mutation, then this fact, along with the differences
in Vx/Ja gene usage and in K rearrangements, would sug-
gest that 4143 arose from a completely different B cell
precursor. Thus, the B cell precursors for the hybridoma group
specific for the D serotype comprised at least two, probably
three, and possibly five different pre-B cell clones, all with
the same N/D amino acid sequence.
We found only a few mice (4/60) that responded to infec-
tion with high circulating ariti-CNPStiter. The lack of serum
antibody in most mice is consistent with an earlier observa-
tion that anti-CNPS antibodies are not detectable in infected
mice (48). A similar phenomenon has been described in
humans, where most individuals with cryptococcal disease
lack circulating antibody (11). This lack of response may be
due to the immunological paralysis that has been reported
to follow immunization with CNPS (5-7) . CNPS has prop-
erties ofa T cell-independent (TI) type 2 antigen (49). There
is evidence that the antibody response to CNPS in mice, like
the response to pneumococcal polysaccharide (50), is regu-
lated by suppressor T cells (7). Additional studies have shown
that cryptococcal antigen preparations can induce suppressor
T cells (51). Our inability to obtain hybridomas producing
anti-CNPS mAbs from the spleens of two infected animals
with low serum titers to CNPS (1:200 or less) is consistent
with few antibody-producing cells in those spleens at the time
fusion.
Given that CNPS has only a few immunogenic determinants
(9) and that the antibody response to some of these deter-
minants is highly restricted, one explanation for the paucity
of responder mice is that only occasional mice have precursor
B cells that can respond to CNPS. However, this is unlikely
since most animals do respond to optimal doses of polysac-
charide immunization (49) and to conjugates of CNPS and
protein (19). This leads us to believe that the few animals
that responded did so because, before infection, they had ex-
panded the number ofB cells that could produce CNPS-specific
antibodies. It is possible that such an expanded pool of B
cells could escape from immunological paralysis either be-
cause ofthe greater number ofB cells or because the expanded
pool contained cells that couldno longer be suppressed. The
fact that we were able to recover six IgM hybridomas with
identical CDR3 sequences from one animal certainly indi-
cates that this particular B cell clone was greatly expanded
at the time of the fusion, and raises the possibility that it
might have been expanded before infection. This could haveresulted indirectly from an idiotype-antiidiotype network or
directly from exposure to a crossreacting antigen. This latter
possibility is supported by the fact that most of the responders
were older mice: 3 of 12 9-12-mo-old mice had a high titer
response, whereas only 1 of 48 adult mice that were <6 mo
old responded. Another studythat showed unresponsiveness
to infection used 3-4-mo-old mice (48).
If the responder mice were able to make an antibody re-
sponse because they had prior exposure to a crossreactive an-
tigen, that antigen could have been another polysaccharide
(52), or even a protein, since protein epitopes can resemble
carbohydrate (53). Since CNPS is a TI antigen (49), it is pre-
sumably unable to induce a secondary immune response (54).
However, TI antigens are capable of activating pre-existing
memory cells (54-56). The IgM hybrrdomms lack somatic
mutations and reflect a TI response to a D-specific epitope
in CNPS. However, the 4H3 hybridoma has somatic muta-
tions in both VH and VL, which may have occurred in the
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